Sanctuary Advisors LLC Purchases 2,656 Shares of Moderna, Inc. (NASDAQ:MRNA)

Sanctuary Advisors LLC grew its position in Moderna, Inc. (NASDAQ:MRNA) by 14.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,987 shares of the company’s stock after buying an additional 2,656 shares during the period. Sanctuary Advisors LLC’s holdings in Moderna were worth $861,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Blue Trust Inc. boosted its holdings in Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares in the last quarter. Wilmington Savings Fund Society FSB increased its holdings in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after acquiring an additional 587 shares in the last quarter. Larson Financial Group LLC raised its position in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. Rakuten Securities Inc. boosted its stake in Moderna by 477.3% in the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after purchasing an additional 778 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its position in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Evercore ISI set a $50.00 price target on shares of Moderna in a report on Friday, February 14th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Barclays cut Moderna from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Finally, Morgan Stanley decreased their target price on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday, January 15th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $60.63.

Moderna Stock Down 7.4 %

MRNA opened at $31.09 on Friday. The firm’s fifty day simple moving average is $37.64 and its two-hundred day simple moving average is $51.61. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The company has a market cap of $11.96 billion, a price-to-earnings ratio of -3.35 and a beta of 1.59.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.